WHO Expert Committee Pre-Review Finds Kratom Not Warranting International Control — But Flags Significant Research Gaps

Why it matters

The WHO's Expert Committee on Drug Dependence conducted its most comprehensive official review of kratom to date in 2021, evaluating whether kratom should be internationally scheduled — a decision that would have cascading effects on the 15+ million Americans who use kratom.

The big picture

The WHO's 44th ECDD pre-review is one of the most consequential official documents in kratom's regulatory history. Its conclusion that kratom does not currently warrant international scheduling under UN conventions helped preserve legal access in most countries, but the flagged research gaps — especially around human pharmacokinetics — continue to drive policy uncertainty.

Key findings

• • Kratom leaf contains 50+ alkaloids; mitragynine comprises up to two-thirds of alkaloid content while 7-OH is only ~1% (but also formed in vivo from mitragynine metabolism)
• • Both mitragynine and 7-OH are partial mu-opioid receptor agonists; morphine is actually 8–10× more potent than 7-OH at the receptor, contrary to common framing
• • Kratom alkaloids are "biased agonists" — they activate the G-protein intracellular pathway but not the beta-arrestin pathway, which may explain reduced respiratory depression relative to classical opioids
• • No human bioavailability data exist for mitragynine or 7-OH; extrapolation from animal studies is unreliable, making accurate human dose-effect relationships unknown
• • Typical U.S. daily dose: 2–6g powder; heavy users may ingest up to 20g; mitragynine raises drug-drug interaction concerns via CYP450 enzyme inhibition

What they say

WHO Expert Committee on Drug Dependence, 44th Meeting, Geneva, October 2021. Comprehensive pre-review of published literature, national questionnaire responses, and pharmacological data.

Bottom line

The WHO's formal determination that kratom does not meet criteria for international scheduling remains the strongest evidence-based policy anchor for advocates of continued legal access — but the committee's call for more human research has not been fully answered in the years since.